Ionis Pharmaceuticals Inc

IONS: XNAS (USA)
View Stock Summary
Morningstar Rating for StocksFair ValueEconomic MoatCapital Allocation
VZLOCK|#M?dLOCK|sR&pcw

Ionis Earnings: Strong Commercial Launch of Tryngolza; Positive Long-Term Outlook

Narrow-moat Ionis reported strong first-quarter results, highlighted by a 10% increase in revenue year over year, driven by the strong launch of Tryngolza (olezarsen). Ionis is tracking our expectations, and we maintain our fair value estimate of $69 per share. We view the shares as very undervalued, trading at an attractive entry point for long-term investors.

Sponsor Center